- Details
- Alicia Morgans and Neal Shore discuss the integration of the newly-approved Lutetium-617 into clinical practice for the treatment of advanced prostate cancer. The conversation revolves around the revolutionary potential of theranostics, where radiopharmaceuticals are linked with antibodies, such as PSMA. They further analyze the VISION trial, which demonstrated survival and quality of life benefit...
|
- Details
- Alicia Morgans speaks with Cora Sternberg about precision medicine's transformative impact on prostate cancer treatment. A key topic is the TALAPRO-2 study, which examines the efficacy of the PARP inhibitor talazoparib in combination with enzalutamide in treating metastatic castration-resistant prostate cancer (CRPC). The study's positive findings suggest significant benefits for patients with BRC...
|
- Details
- Alicia Morgans engages with Silke Gillessen to discuss the upcoming APCCC conference in 2024. The conference seeks to address some of the major questions in clinical practice such as the management of biochemical relapse after radical prostatectomy and the application of novel endocrine agents plus PARP inhibitors in first line mCRPC treatments. Side effects and their management, especially those...
|
- Details
- Neeraj Agarwal articulates his vision for the future of treating metastatic castration-sensitive prostate cancer (CSPC). Agarwal delves into the remarkable therapeutic advancements in the past decade, notably, the shift to doublet and triplet therapies. Despite these developments, he draws attention to the underutilization of such treatments in real-world settings due to various barriers. Primaril...
|
- Details
- Alicia Morgans engages in a conversation with Bridget Koontz about the NRG-GU-011 (NRG PROMETHEAN) study. This double-blinded, randomized phase II trial focuses on prostate cancer patients with biochemical recurrence and oligometastatic disease, detected via PET scan. The study explores the potential benefits of radiation, specifically SBRT, either alone or combined with Relugolix for six months....
|
- Details
- In this conversation, Alicia Morgans and Neeraj Agarwal discuss the TALAPRO-2 trial, a phase three study investigating the effectiveness of combining ADT plus enzalutamide plus talazoparib in treating first line metastatic castrate-resistant prostate cancer. Agarwal presents the study's quality of life data at ASCO 2023, revealing the experimental arm significantly delayed the deterioration of pat...
|
- Details
- Alicia Morgans interviews Matthew Smith about the ARASENS Study and its implications for patients focusing on the study's secondary endpoints, including time to pain progression and skeletal-related events, which are crucial for understanding patient well-being. He emphasizes that the study included a diverse range of patients with varying disease characteristics, and the overall survival benefit...
|
- Details
- In a discussion between Alicia Morgans and Alberto Bossi, they delved into the PEACE-1 data. Professor Bossi outlined the European study initiated by himself and Karim Fizazi, focusing on the potential impact of radiotherapy and abiraterone on the prognosis of metastatic prostate cancer patients. Discussing the study's results, Professor Bossi revealed no overall survival benefit from radiotherapy...
|
- Details
- Alicia Morgans host Fatima Karzai and Rana McKay to explore the National Cancer Institute Natural History Study. This study focuses on prostate cancer patients with unusual mutations and exceptional responses to treatments, aiming to understand their disease progression over time. The trial, conducted across multiple sites including UCSD, follows participants longitudinally, particularly those wit...
|
- Details
- In this conversation, Andrea Miyahira is joined by a research team including Anke Augspach, Rahul Kanadia, and Mark Rubin. They discuss their paper, "Minor Intron Splicing is Critical for Survival of Lethal Prostate Cancer". The paper dissects the role of minor introns, which constitute less than 0.5% of all introns, in gene expression and their involvement in prostate cancer onset and progression...
|
